180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) announced on January 4, 2023, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company received a letter confirming that its common stock's closing bid price remained at or above $1.00 per share for 10 consecutive business days. This compliance is crucial for maintaining its listing on the Nasdaq Stock Market. 180 Life Sciences focuses on developing clinical programs aimed at addressing significant unmet medical needs, particularly through a novel treatment for inflammatory disorders.

Positive

• Regained compliance with Nasdaq's Minimum Bid Price Requirement.
• Closing bid price maintained above $1.00 for 10 consecutive business days.

Negative

• None.

PALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company’s common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement.

About 180 Life Sciences Corp.

180 Life Sciences Corp. is a clinical-stage biotechnology company driving ground-breaking studies into clinical programs which are seeking to address major unmet medical needs. The Company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

Investors:

Jason Assad
Director of IR
180 Life Sciences Corp
(678) 570-6791
Jason@180lifesciences.com

 

FAQ

What does it mean for 180 Life Sciences to regain compliance with Nasdaq?

Regaining compliance means that 180 Life Sciences has met the minimum bid price requirement set by Nasdaq, allowing it to remain listed on the stock exchange.

When did 180 Life Sciences receive notice of compliance from Nasdaq?

180 Life Sciences received notice of compliance on January 4, 2023.

What was the closing bid price for 180 Life Sciences to regain compliance?

The closing bid price for 180 Life Sciences needed to be at or above $1.00 per share.

What is the focus of 180 Life Sciences Corp.?

180 Life Sciences focuses on developing clinical programs to address major unmet medical needs, particularly in treating inflammatory disorders.